Summary & Overview
CPT 81407: Advanced Molecular Pathology Genetic Analysis
CPT code 81407 represents a high-complexity molecular pathology procedure used for extensive genetic analysis, including DNA sequencing of multiple exons and genes. This code is critical in the landscape of genetic testing, enabling clinicians to identify mutations, duplications, or deletions across a broad range of genetic material. The procedure is typically performed in laboratory settings and is essential for diagnosing hereditary conditions, guiding treatment decisions, and informing genetic counseling.
Major national payers such as Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare provide coverage for services billed under CPT code 81407. The publication offers insights into payer coverage policies, clinical benchmarks, and recent policy updates relevant to molecular pathology and genetic testing. Readers will gain an understanding of the clinical context for this code, including its role in screening for genetic and chromosomal anomalies, and how it fits within broader trends in precision medicine.
Key topics include payer coverage details, clinical indications, and the importance of advanced genetic testing in modern healthcare. The summary also highlights related codes and modifiers commonly used in billing, providing a comprehensive overview for stakeholders interested in laboratory-based molecular diagnostics.
CPT Code Overview
CPT code 81407 is designated for advanced molecular pathology procedures, specifically Level 8 complexity. This code covers the analysis of 26‑50 exons by DNA sequence analysis, mutation scanning, or duplication/deletion variants of more than 50 exons, as well as sequence analysis of multiple genes on a single platform. The service type is molecular pathology and genetic testing, typically performed in a laboratory setting where the technical component is emphasized. This procedure is integral for comprehensive genetic screening and diagnosis, supporting clinical decision-making in a variety of specialties.
Clinical & Coding Specifications
Clinical Context
A patient is referred for advanced genetic testing due to a suspected hereditary disorder or chromosomal abnormality. The clinical workflow involves a physician (such as in Family Medicine, Internal Medicine, Obstetrics & Gynecology, or Pathology) ordering a molecular pathology procedure. The laboratory performs DNA sequence analysis covering 26-50 exons or mutation scanning/duplication/deletion analysis of more than 50 exons, potentially involving multiple genes on a single platform. The results are used to inform diagnosis, guide genetic counseling, or support screening for genetic and chromosomal anomalies.
Coding Specifications
-
Modifiers:
26: Professional Component – Used when only the interpretation of the test is performed by the physician.TC: Technical Component – Used when only the laboratory performs the technical aspects of the test.91: Repeat Clinical Diagnostic Laboratory Test – Used when the same test is repeated on the same patient.
-
Provider Taxonomies:
| Taxonomy Code | Specialty |
|---|---|
207ZP0007X | Pathology |
207L00000X | Anatomic Pathology |
207Q00000X | Family Medicine |
207R00000X | Internal Medicine |
207V00000X | Obstetrics & Gynecology |
These specialties represent providers who may order or interpret molecular pathology procedures.
Related Diagnoses
-
Z13.79: Encounter for other screening for genetic and chromosomal anomalies- Used when the procedure is performed as part of a screening for genetic or chromosomal disorders.
-
Q99.9: Chromosomal abnormality, unspecified- Applied when a chromosomal abnormality is suspected but not yet specified.
-
Z84.81: Family history of carrier of genetic disease- Indicates testing due to a family history of genetic disease carriers.
-
Z31.430: Encounter for genetic counseling- Used when the procedure supports genetic counseling sessions.
-
E88.89: Other specified metabolic disorders- Relevant when testing is performed to investigate metabolic disorders with a suspected genetic basis.
Related CPT Codes
81507: Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
81507 is related to 81407 as both involve DNA sequence analysis for genetic conditions. 81507 is specifically used for prenatal screening of fetal chromosomal abnormalities, while 81407 covers broader molecular pathology procedures. These codes may be used in similar clinical workflows but are not typically billed together; rather, they serve as alternatives depending on the clinical indication.
National Reimbursement Benchmarks
National mean rates for CPT code 81407 show that Blue Cross Blue Shield has the highest average reimbursement at $788.12, while UnitedHealth Group is the lowest among the major commercial payers at $669.13. The BUCA (average commercial) mean rate stands at $718.54. Medicare rates are not available in the input, so a comparison to Medicare is not possible.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna exhibits the widest spread at $745.50, indicating substantial variability in contracted rates. In contrast, Aetna has the tightest range at $236.00, suggesting more consistent reimbursement levels. Blue Cross Blue Shield, UnitedHealth Group, and BUCA fall in between, with ranges of $234.67, $415.00, and $370.81, respectively.
The table and chart below present the full breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.